GENENTECH, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study of Dulanermin in Combination With Rituximab in Subjects With Follicular and Other Low Grade, CD20+, Non-Hodgkin's Lymphomas
- First Posted Date
- 2006-11-17
- Last Posted Date
- 2011-11-23
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT00400764
A Study of Tenecteplase for Restoration of Function in Dysfunctional Hemodialysis Catheters
Phase 3
Completed
- Conditions
- Dysfunctional Hemodialysis Catheters
- Interventions
- Drug: placebo
- First Posted Date
- 2006-11-06
- Last Posted Date
- 2010-06-03
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT00396032
A Study of Tenecteplase for Restoration of Function in Dysfunctional Central Venous Catheters
Phase 3
Completed
- Conditions
- Dysfunctional Central Venous Access Catheters
- Interventions
- First Posted Date
- 2006-11-06
- Last Posted Date
- 2011-04-27
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 251
- Registration Number
- NCT00396318
A Study of Tenecteplase for Restoration of Function in Dysfunctional Central Venous Catheters
Phase 3
Completed
- Conditions
- Dysfunctional Central Venous Access Catheters
- Interventions
- Drug: placebo
- First Posted Date
- 2006-11-06
- Last Posted Date
- 2010-08-10
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT00395876
A Study of Tenecteplase for Restoration of Function in Dysfunctional Hemodialysis (HD) Catheters
- First Posted Date
- 2006-11-06
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 223
- Registration Number
- NCT00396253
A Study of Avastin in Combination With Chemotherapy for Treatment of Colorectal Cancer and Non-Small Cell Lung Cancer (ARIES)
Completed
- Conditions
- Colorectal CancerNon-Small Cell Lung Cancer
- First Posted Date
- 2006-10-16
- Last Posted Date
- 2022-12-12
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 3998
- Registration Number
- NCT00388206
A Study to Evaluate the Effects of Efalizumab on Immune Responses in Subjects With Moderate Plaque Psoriasis
Phase 1
Completed
- Conditions
- Plaque Psoriasis
- First Posted Date
- 2006-09-29
- Last Posted Date
- 2006-09-29
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT00382512
A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g
- First Posted Date
- 2006-09-28
- Last Posted Date
- 2009-12-15
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT00382148
A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus
Phase 3
Terminated
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- First Posted Date
- 2006-09-28
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT00381810
- Locations
- 🇺🇸
Arizona Arthritis & Rheumatology Research, Pllc, Paradise Valley, Arizona, United States
🇺🇸Eden Medical Center San Leandro Hospital, San Leandro, California, United States
🇺🇸Intermountain Research Center, Boise, Idaho, United States
An Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization Secondary to AMD or Macular Edema Secondary to RVO
Not Applicable
Completed
- Conditions
- Choroidal Neovascularization, Age-related Macular Degeneration
- Interventions
- First Posted Date
- 2006-09-22
- Last Posted Date
- 2017-05-11
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 853
- Registration Number
- NCT00379795
© Copyright 2025. All Rights Reserved by MedPath